Moderna's US stock rose more than 2.4% before the market, and the company's mRNA influenza vaccine was officially approved for listing by the US FDA. This is the first mRNA influenza vaccine approved in the world.

Moderna's US stock rose more than 2.4% before the market, and the company's mRNA influenza vaccine was officially approved for listing by the US FDA. This is the first mRNA influenza vaccine approved in the world.